Clinical Trials · NCT03115099
A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 80
- Start date
- May 2017
- Locations
- 2 sites, Singapore
- Primary endpoint
- Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration